Chimeric Therapeutics Ltd (chm) Logo

Chimeric Therapeutics Ltd (CHM)

___:___ · Healthcare

CHM Chart


CHM's Principal Activity is the chimeric is a biotechnology company developing a cancer cell therapy drug.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -11.40%


Market Capitalisation
ASX Rank 1,203 of 2,314
Sector Rank 106 of 198

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies CDX / CMP / ATH
EPS $0.00
DPS $0.00
NTA per share $0.00

Broker Consensus

CHM is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Chimeric Therapeutics Limited (CHM) is a biotechnology company developing a breakthrough cancer cell therapy drug which was discovered at the prestigious City of Hope Cancer Centre in Los Angeles, California. CHM is developing ground breaking CAR T cell therapy.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Carlton South VIC 3053
Registry BoardRoom
Auditor Grant Thornton Audit Pty Ltd
Date Listed 18 Jan 2021

Upcoming Calendar (Forecasted)

Date Event
25/02/2022 Report (Interim)
30/08/2022 Report (Prelim)
28/09/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Jennifer Chow Chief Executive Officer,Managing Director Aug 2021 Director Bio icon

Ms Jennifer Chow

Chief Executive Officer,Managing Director

Ms Chow has more than 20 years of commercial strategy and marketing experience focused on cellular therapy, hematology and oncology. Prior to joining Chimeric, Ms Chow was Head of Global Marketing, Analytics and Commercial Operations at global CAR T company Kite Pharmaceuticals (acquired by Gilead Sciences in 2017). She was previously Global Cell Therapy Commercial Lead at Celgene Corporation and was responsible for designing and developing the global CAR T commercial strategy and operating model. Ms Chow was also formerly at Roche, Nycomed/Takeda and Schering Canada.

Dr George Matcham Non-Executive Director Jul 2021 Director Bio icon

Dr George Matcham

Non-Executive Director

Dr Matcham has experience in the biopharma sector, following worked for three decades with cell therapy giant Celgene Corporation. He joined Celgene in its infancy in 1988 when the company was a 30-person startup, retiring in 2018. At Celgene, Dr Matcham championed the introduction of cellular immunotherapy and led the establishment of cell therapy and biologics technical development. At Celgene, Dr Matcham held several senior positions, including Chief Operations Officer of Celgene Cellular Therapeutics and Senior Vice President of CAR T CMC Development, where he oversaw clinical supply. In recent years, Dr Matcham has also served on the board and as an advisor at Instil Bio throughout its financing rounds and IPO.

Ms Cynthia Elkins Non-Executive Director Feb 2021 Director Bio icon

Ms Cynthia Elkins

Non-Executive Director


Ms Leslie (Mi Ok) Chong Non-Executive Director Aug 2020 Director Bio icon

Ms Leslie (Mi Ok) Chong

Non-Executive Director

Ms Chong has more than 21 years of oncology experience with clinical development experience in global Phase I-III studies from start-up to registration. Ex Senior Clinical Program Lead at Genentech, one of the biotech businesses developing therapies across all cancer indications. Previously, he was worked at GlaxoSmithKline (NYSE: GSK) and Exelixis (NASDAQ: NEXEL) in cancer therapy development. He has Development experience in oncology with small molecules, immunotherapies, cancer vaccines, oncolytic viral therapies, epigenetics, monoclonal antibodies et al. Ms Chong has experience in clinical development of brain cancer therapies. Ms Chong is currently Chief Executive Officer and Managing Director of Imugene Limited (ASX:IMU); and Non-Executive Director of Cure Brain Cancer Foundation. She is also Chair of the risk management committee of CHM.

Dr Lesley Russell Non-Executive Director Aug 2020 Director Bio icon

Dr Lesley Russell

Non-Executive Director

Dr Russell has more than 25 years of senior international operational and leadership experience having worked at Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), Cephalon (NASDAQ: CEPH) and Teva (NYSE: TEVA). As Chief Medical Officer and Chief Operating Officer Dr Russell has experience in the therapeutic areas of hematology, oncology, neurology, psychiatry, pain and inflammation, respiratory medicine and stem cell therapy. Dr Russell has knowledge and experience with new drug development along with CART therapies. Dr Russell is currently a Non-Executive Director of Enanta Pharmaceuticals (NASDAQ: ENTA) and Imugene Ltd (ASX:IMU). He is also member of the risk management committee of CHM.

Mr Paul Alex Hopper Founder,Executive Chairman,Executive Director Feb 2020 Director Bio icon

Mr Paul Alex Hopper

Founder,Executive Chairman,Executive Director

Mr Hopper has over 25 years experience in the medical, healthcare & life sciences sectors. His experience covers fund raising in Australia, Asia, US and Europe, and he has experience in corporate governance, risk and strategy. Focussed on start-up and growth companies, he has served as either Founder, Chairman, non-executive director, or Chief Executive Officer, of more than fourteen companies in the US, Australia and Asia. Previous and current Boards include Viralytics (ASX: VLA), Imugene (ASX: IMU), pSivida (ASX: PSD), Polynoma (wholly owned subsidiary of HKG:0775), Somnomed (ASX: SOM), Suda (ASX: SUD), C19 Therapeutics Pty Ltd, and Prescient Therapeutics (ASX: PTX).

Mr Nathan Jong Joint Company Secretary N/A
Mr Phillip Hains Chief Financial Officer,Joint Company Secretary N/A

Director Transactions

CHM directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
04/08/21 George Matcham Buy +500,000 $0.332 $166,000 On-market trade
08/03/21 Cynthia Elkins Buy +24,800 $0.318 $7,881 On-market trade
29/01/21 Leslie (Mi Ok) Chong Buy +7,300 $0.326 $2,378 On-market trade
20/01/21 Leslie (Mi Ok) Chong Buy +5,000 $0.39 $1,950 On-market trade

Director Interests

The current holdings of CHM directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Jennifer Chow 30/08/2021 670,498 N/A 8,291,495 N/A
George Matcham 04/08/2021 500,000 N/A N/A N/A
Cynthia Elkins 08/03/2021 0 24,800 N/A N/A
Leslie (Mi Ok) Chong 29/01/2021 12,300 N/A 2,750,000 N/A
Lesley Russell 28/08/2020 N/A N/A 2,750,000 N/A
Paul Hopper 02/02/2020 N/A 77,777,778 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Jan 12, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Moreglade Pty Limited 77,777,778 23.53%
CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C) 34,650,000 10.48%
HSBC Custody Nominees (Australia) Limited - A/C 2 12,750,000 3.86%
Accbell Nominees Pty Ltd 12,002,140 3.63%
City Of Hope 11,633,334 3.52%
Christine Brown 11,522,634 3.49%
Michael E Barish 11,522,634 3.49%
HSBC Custody Nominees (Australia) Limited 7,887,969 2.39%
HSBC Custody Nominees 6,537,500 1.98%
CS Fourth Nominees Pty Limited (Settlement A/C) 5,050,000 1.53%
Morgan Stanley Australia Securities (Nominee) Pty Limited (No 1 Account) 5,000,000 1.51%
Citicorp Nominees Pty Limited 4,490,156 1.36%
National Nominees Limited 4,250,000 1.29%
Hudson Bay Master Fund Ltd 2,666,667 0.81%
Jarl Mohn (The Mohn Family A/C) 2,304,527 0.70%
Australian Direct Investments Pty Limited (The Adi Super Fund A/C) 2,304,527 0.70%
Greenhill Road Investments Pty Ltd (No 2 A/C) 1,333,334 0.40%
Finclear Nominees Pty Ltd (Accumulation Entrepot A/C) 1,298,705 0.39%
Cure Brain Cancer Foundation 1,250,000 0.38%
Dylide Pty Ltd 1,152,263 0.35%
Horatia Isabelle Hopper 1,152,263 0.35%
Alexandra Jane Hopper 1,152,263 0.35%
Andrew Banks & Associates Pty Ltd (The A R B A/C) 1,152,263 0.35%
Ashlaw Pty Limited (The Whitehead Super Fund A/C) 1,152,263 0.35%
India Lucy Hopper 1,152,263 0.35%
Robert Bain Thomas 1,152,263 0.35%
Scarlett Augusta Hopper 1,152,263 0.35%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 1 14 99 896 239 1,249

Substantial Shareholders

No Substantial Shareholders for CHM in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
18-01-21 Paul Hopper 82,386,830 -- 24.92

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
CHM Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.